Cited by 354CAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses

3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

Open access
Schnalzger, Theresa E, de Groot, Marnix HP, Zhang, Congcong, Mosa, Mohammed H, Michels, Birgitta E, Röder, Jasmin, Darvishi, Tahmineh, Wels, Winfried S +1 more·2019·The EMBO Journal

Abstract

Immunotherapy using chimeric antigen receptor (CAR)-engineered lymphocytes has shown impressive results in leukemia. However, for solid tumors such as colorectal cancer (CRC), new preclinical models are needed that allow to test CAR-mediated cytotoxicity in a tissue-like environment. Here, we developed a platform to study CAR cell cytotoxicity against 3-dimensional (3D) patient-derived colon organoids. Luciferase-based measurement served as a quantitative read-out for target cell viability. Additionally, we set up a confocal live imaging protocol to monitor effector cell recruitment and cytolytic activity at a single organoid level. As proof of principle, we demonstrated efficient targeting in diverse organoid models using CAR-engineered NK-92 cells directed toward a ubiquitous epithelial antigen (EPCAM). Tumor antigen-specific cytotoxicity was studied with CAR-NK-92 cells targeting organoids expressing EGFRvIII, a neoantigen found in several cancers. Finally, we tested a novel CAR strategy targeting FRIZZLED receptors that show increased expression in a subgroup of CRC tumors. Here, comparative killing assays with normal organoids failed to show tumor-specific activity. Taken together, we report a sensitive in vitro platform to evaluate CAR efficacy and tumor specificity in a personalized manner.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/embj.2018100928

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Non-tumor cells from adjacent normal tissue can be used to develop control healthy organoids to confirm tumor-specific efficacy of tested drugs.

    “Non-tumor cells from adjacent normal tissue in biopsies or surgically resected samples can be used to develop control healthy organoids to confirm the tumor-specific efficacy of the tested drugs155.”

    From Organoids (2022) · cites this paper as [155]

    The Patient samples section says healthy colon organoids were derived from non-pathological mucosa, including tumor-adjacent tissue collected after resection. The CAR targeting of tumor neoantigens section uses healthy organoids as controls to assess tumor-specific killing. The tested treatment was CAR-mediated cytotoxicity, however, not drugs generally; the paper does not establish the claimed drug-testing application. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schnalzger, T. E., de Groot, M. H., Zhang, C., Mosa, M. H., Michels, B. E., Röder, J., Darvishi, T., Wels, W. S., & Farin, H. F.
Affiliations
  • University of Konstanz (DE)
  • German Cancer Research Center (DE)
  • Goethe University Frankfurt (DE)
Corresponding author
Farin, Henner F
Venue
The EMBO Journal
Published
2019-04-29
Volume
38
Issue
12
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W2942656692
Cited by
354
References
57
Citations by year
2026: 45 · 2025: 60 · 2024: 62 · 2023: 63 · 2022: 47 · 2021: 41 · 2020: 29 · 2019: 7
FWCI
12.96
Type
journal article
Language
en
Open access
Locations
  • The EMBO Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Frankfurt Cancer Institute (III L 5 ‐ 519/03/03.001 ‐ (0015))
  • German Cancer Consortium
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chimeric antigen receptor, colorectal cancer, 3D organoids, EpCAM, EGFRvIII, Frizzled receptors, tumor antigen specificity, luciferase reporter
MeSH terms
Receptors, Chimeric Antigen, Cells, Cultured, Cytotoxicity, Immunologic, Humans, Models, Biological, Organoids, Receptors, Antigen, T-Cell, Colorectal Neoplasms, Genetic Therapy, Immunotherapy, Adoptive, Tissue Culture Techniques, Tissue Scaffolds, HEK293 Cells, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review